7.3 C
London
Tuesday, March 5, 2024

Emerging Growth Conference 68 March 6 & 7 - Register now

More Headlines

Extending Commercialisation of PureGRAPH across a wide range of industries

0
Highlights Home building: UK eco-home building company continues to use graphene enhanced construction materials to improve fire retardancy and strength Automotive Lubricants: Graphene enhanced...

Epazz Holdings ZenaDrone Was Awarded Phase 1 US Air Force SBIR...

0
Epazz, Inc. (OTC: EPAZ), a mission-critical provider of drone technology, blockchain mobile apps and cloud-based business software solutions, announced today one of its holdings,...

12 Best Bitcoin Mining Software for Windows PC

0
With the advent of blockchain technology, hundreds of different cryptocurrencies have appeared. Today, mining is available to almost everyone. Just make sure your computer...

AD-214 RETURNS TO CLINICAL STUDIES

0
Key points: First dosing of AD-214 achieved in Phase I extension study On track to obtain interim results in 2023, full results in...

Unlocking Chronic Diseases with Next-Gen i-body Platform Technology from AdAlta (1AD)

0
Unlocking Chronic Diseases with Next-Gen i-body Platform Technology from AdAlta (1AD) 1AD stock carries a dramatically undervalued profile against its blue-sky upside target Emerging Growth Report...
Epazz, Inc. (OTC: EPAZ) Holdings: ZenaPay Inc. Receives Preorders of ZenaDrone with the Now Corporation for its ZenaDrone Smart Farming Solution

Epazz, Inc. (OTC Pink: EPAZ) Tokens, Funding for over $2 million in Revenue, and...

0
Epazz, Inc. (OTC Pink: EPAZ) a mission-critical provider of drone technology, blockchain cryptocurrency mobile apps and cloud-based business software solutions, announced today that CryObo...

$1.87 million raised in oversubscribed Shortfall facility

0
MELBOURNE Australia, 13 July 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased...

New AD-214 Data Links Phase I Results With Efficacy; De-Risks Clinical Dosing Schedule

0
Key points: • New data favourably links AD-214 preclinical animal studies and Phase I human clinical trial results to provide important dose frequency insights • AD-214 is designed to...

AdAlta (ASX: 1AD) IMPORTANT PHASE I EXTENSION CLINICAL STUDY OF AD-214 APPROVED

0
29 June 2023 ASX Announcement IMPORTANT PHASE I EXTENSION CLINICAL STUDY OF AD-214 APPROVED Key highlights: Human Research Ethics Committee (HREC) has approved Phase I extension...

Understanding the Different Approaches in Investing in Cryptocurrency

0
The cryptosphere, teeming with opportunity and complexity, is redefining the boundaries of traditional investing. Cryptocurrencies, which were once the obscure fascination of technophiles, have...